Writing anything positive about LipoScience (LPDX)
was a losing move in 2013, as the stock moved steadily down throughout
the year. Making matters worse, it wasn't just a "the market doesn't get
it" phenomenon as the company logged three straight quarters with
revenue year-on-year revenue declines - something nobody wants to see
from a company that is supposed to be in the early days of a major
product launch.
I continue to believe there's still hope here,
even if that hope has been pushed out a few years. Clinical studies are
backing up the validity and utility of the LDL particle assessment
approach and I believe that there is a strong argument to make here for
LipoScience's NMR LipoProfile test being a valuable behavior-changing
test. The problem is that it's going to take time for the company to
sell payers and doctors on that value. The potential value in the shares
is great, but so too is the risk and there are no guarantees that
LipoScience will make it to that critical inflection point where
revenues and profits begin to flow into the company.
Follow this link to the full article at Seeking Alpha:
LipoScience Facing A Long, Hard Slog
No comments:
Post a Comment